Regulatory requirements for laboratory developed tests in the United States

被引:2
作者
Bennett, Shannon A. [1 ]
Conn, Chelsea M. [1 ]
Gill, Hillary E. [1 ]
Holmen, Brenda K. [1 ]
Mcdevitt, Tasha M. [1 ]
Miliander, Corrisa L. [1 ]
Uphoff, Benjamin D. [1 ]
Hanson, Curtis A. [1 ]
机构
[1] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA
关键词
Quality management; Regulations; Compliance; CAP; NYS; FDA;
D O I
10.1016/j.jim.2025.113813
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Clinical laboratories in the United States are governed by a variety of required regulatory and optional accreditation bodies. All laboratories must comply with the federal Clinical Laboratory Improvement Amendments (CLIA) or state equivalents, while some laboratories choose additional accreditation partners. While not a regulatory body, International Standards Organization (ISO) is an internationally recognized quality system that includes best practices specific to clinical laboratories. Likewise, the Clinical Laboratory Standards Institute (CLSI) publishes guidance documents that include best practices for test validation. The Food and Drug Administration (FDA) has historically exercised enforcement discretion in regulating laboratory developed tests (LDTs), but that approach has changed with publication of the FDA's LDT final rule.
引用
收藏
页数:5
相关论文
共 23 条
[1]  
[Anonymous], 2017, Discussion Paper on Laboratory Developed Tests (LDTs)
[2]  
[Anonymous], Medical Test Sites
[3]  
[Anonymous], 2024, Recognized Consensus Standards: Medical Devices
[4]  
[Anonymous], 2023, Verifying Accurate Leading-edge IVCT Development Act (Draft).
[5]  
Badrick Tony, 2013, Clin Biochem Rev, V34, P43
[6]  
Clinical Laboratory Evaluation Program (CLEP) Guide, About us
[7]  
CMS, CLIN LAB IMPROVEMENT
[8]  
ecfr, Part 493-Laboratory Requirements
[9]  
FDA, LAB DEV TESTS
[10]  
fda, CLIA Categories